Novel long-circulating liposomes containing peptide library-lipid conjugates: synthesis and in vivo behavior.
Rapid uptake of intravenously injected liposomes by the mononuclear phagocyte system has limited their use as drug delivery vehicles. Recently, various long-circulating liposomes have been prepared by incorporating glycolipids or other amphiphilic molecules into the lipid bilayer of conventional liposomes. The purpose of the present study was to design a new class of biodegradable membrane modifiers that would increase the half-life of liposomes in vivo. Using solid-phase peptide synthesis, synthesized were 30-residue random libraries consisting of a random sequence of glycine, beta-alanine and gamma-aminobutyric acid. The libraries were coupled to stearic acid (SA) or phosphatidylethanolamine (PE). The resulting amphiphilic conjugates were mixed with egg phosphatidylcholine (PC) and cholesterol (Chol) in a 6:47:47 ratio, and unilamellar liposomes were prepared. For comparison, plain PC/Chol (50:50) liposomes, as well as liposomes containing polyethylene glycol (PEG)-SA/PC/Chol (6:47:47) and PEG-PE/PC/Chol (6:47:47) were also prepared. Calcein was entrapped in the liposomes, which were given intravenously to rats at a dose of 9.2 mumol lipid/kg, and the amount of intact liposomes present in serum was followed with time. While the conventional liposomes had a short elimination half-life (28 min), the liposomes modified with library-PE had a much longer half-life (170 min), while library-SA provided no improvement of the liposome pharmacokinetics. PEG-PE greatly improved the half-life of the liposomes (400 min) while PEG-SA only provided a marginal improvement. All liposome preparations were cleared in a biphasic fashion. In conclusion, a novel biodegradable lipopeptide conjugate was designed that endows liposomes with a prolonged circulation time in vivo. The pharmacokinetic profile of these modified liposomes was drastically improved over that of conventional liposomes. Since the library is prepared by solid-phase synthesis, length and/or composition could easily be modified in order to modulate the clearance profile of the liposomes. Tailoring of the pharmacokinetic profile of the liposomes depending on their intended application may allow for a greater flexibility of use than PEG-PE.
Riché
Estelle L
EL
School of Dentistry, University of North Carolina, Chapel Hill, NC 27599-7360, USA.
Erickson
Bruce W
BW
Cho
Moo J
MJ
D000818:Animals; D001673:Biodegradation, Environmental; D003692:Delayed-Action Preparations; D005452:Fluoresceins / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics; D005998:Glycine / Q000737:chemistry; D006207:Half-Life; D007275:Injections, Intravenous; D008081:Liposomes / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics*; D008297:Male; D019151:Peptide Library; D010455:Peptides / Q000138:chemical synthesis* / Q000737:chemistry; D010714:Phosphatidylethanolamines / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000737:chemistry / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D013229:Stearic Acids / Q000737:chemistry*; D013997:Time Factors; D015091:beta-Alanine / Q000737:chemistry; D005680:gamma-Aminobutyric Acid / Q000737:chemistry
D003692:Delayed-Action Preparations; D005452:Fluoresceins; D008081:Liposomes; D019151:Peptide Library; D010455:Peptides; D010714:Phosphatidylethanolamines; D013229:Stearic Acids; D015091:beta-Alanine; C483858:phosphatidylethanolamine; D011092:Polyethylene Glycols; C031183:stearic acid; D005680:gamma-Aminobutyric Acid; D005998:Glycine; C007740:fluorexon